Biopharmaceutical company AbbVie had a strong year, with revenues growing nearly 23%. Sales for the company’s top-performing immune defense drugs continued to rise in 2021, especially domestically, where revenues for the best-selling Humira drug increased by 7.6%. Humira did not perform as well on the global market, where it was edged out by biosimilar competition, but international revenues for products including plaque psoriasis treatment Skyrizi and rheumatoid arthritis drug Rinvoq rose by several billion dollars each. AbbVie predicted strong growth in 2022 with an increased focus on expanding its products’ coverage in both American and European markets.
Smith Collection—Getty Images

Company Information

As of 8/3/2022
Country
U.S.
Headquarters
North Chicago, Ill.
Industry
Pharmaceuticals
CEO
Richard A. Gonzalez
Company Type
Public
Ticker
ABBV
Revenues ($M)
$56,197
Profits ($M)
$11,542
Market Value ($M)
$264,607
Employees
50,000
Market value as of July 19, 2022.

Key Financials (Last Fiscal Year)

$ millions
% change
Revenues ($M)
$56,197
22.7%
Profits ($M)
$11,542
150%
Assets ($M)
$146,529
-
Total Stockholder Equity ($M)
$15,408
-

Profit Ratios

Profit as % of Revenues
20.5%
Profits as % of Assets
7.9%
Profits as % of Stockholder Equity
74.9%

Earnings Per Share (Last Fiscal Year)

Earnings Per Share ($)
645
EPS % Change (from 2020)
137.1%
EPS % Change (5 year annual rate)
12.2%
EPS % Change (10 year annual rate)
-

Total Return

Total Return to Investors (2021)
32.2%
Total Return to Investors (5 year, annualized)
22%
Total Return to Investors (10 year, annualized)
-

AbbVie Rank History

Historical Data

YearRevenues ($M)Profits ($M)Assets ($M)Total Stockholder Equity ($M)
2021$45,80437.7%$4,616-41.4%$150,565$13,076
2020$33,2661.6%$7,88238.6%$89,115$-8,172
2019$32,75316.1%$5,6877.1%$59,352$-8,446
2018$28,21610.1%$5,309-10.8%$70,786$5,097
2017$25,63812.2%$5,95315.7%$66,099$4,636
SHOW MORE
FortuneDataStore ad
Lists ranking AbbVie
RANK63
Fortune 500 - 2022This year’s Fortune 500 marks the 68th running of ...READ MORE
RANK227
Global 500 - 2022Aggregate sales hit $37.8 trillion last year—an in...READ MORE
RANK72
100 Best Companies to Work For - 2022When it comes to supporting employees, flexibility...READ MORE
RANK6
World's Best Workplaces - 2022...READ MORE